GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » Selling, General, & Admin. Expense

BriaCell Therapeutics (BriaCell Therapeutics) Selling, General, & Admin. Expense : $7.57 Mil (TTM As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. BriaCell Therapeutics's selling, general, & admin. expense for the three months ended in Jan. 2024 was $1.57 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jan. 2024 was $7.57 Mil.


BriaCell Therapeutics Selling, General, & Admin. Expense Historical Data

The historical data trend for BriaCell Therapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Selling, General, & Admin. Expense Chart

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.05 1.50 4.96 7.27 7.94

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.43 1.82 2.54 1.65 1.57

Competitive Comparison of BriaCell Therapeutics's Selling, General, & Admin. Expense

For the Biotechnology subindustry, BriaCell Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Selling, General, & Admin. Expense falls into.



BriaCell Therapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BriaCell Therapeutics  (NAS:BCTX) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


BriaCell Therapeutics Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (BriaCell Therapeutics) Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.
Executives
Jamieson Bondarenko director 402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub director 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin officer: CFO & Secretary MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del officer: Chief Medical Officer 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams director, officer: President & CEO 620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg director 201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago officer: Chief Scientific Officer 2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony director P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0
Marc Lustig director 4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3